BNT166a

BIOLOGICAL3 trials

Sponsors

BioNTech SE

Conditions

MonkeypoxMpoxMpox (Monkeypox)Orthopoxvirus InfectionSmallpox

Phase 1

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

CompletedNCT05988203

BioNTech SEMonkeypox

Start: 2023-09-21End: 2026-03-04Updated: 2026-09-15

Phase 2

A randomized clinical trial investigating the safety, reactogenicity, and immunogenicity after immunization with an mRNA-based mpox vaccine candidate in Africa

Active, not recruitingPACTR202601475113911

BioNTech SEMpox

Start: 2026-02-24Target: 310Updated: 2026-08-03

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

RecruitingNCT07379580

BioNTech SEMpox (Monkeypox), Orthopoxvirus Infection, Smallpox

Start: 2026-02-20End: 2027-06-01Target: 310Updated: 2026-08-11

Related Papers

219. Safety and Immunogenicity of BNT166a, an Investigational Quadrivalent mRNA Mpox Vaccine

Open Forum Infectious Diseases2026-01-01

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease

Cell2024-02-15137 citations